ADC Therapeutics SA (ADCT)
| Market Cap | 145.54M -59.8% |
| Revenue (ttm) | 79.58M +3.0% |
| Net Income | -96.91M |
| EPS | -0.65 |
| Shares Out | 127.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,577,910 |
| Open | 1.110 |
| Previous Close | 1.120 |
| Day's Range | 1.070 - 1.170 |
| 52-Week Range | 0.780 - 4.980 |
| Beta | 1.83 |
| Analysts | Buy |
| Price Target | 3.33 (+192.11%) |
| Earnings Date | Aug 13, 2026 |
About ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue... [Read more]
Financial Performance
In 2025, ADC Therapeutics's revenue was $81.36 million, an increase of 14.85% compared to the previous year's $70.84 million. Losses were -$142.62 million, -9.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ADCT stock is "Buy." The 12-month stock price target is $3.33, which is an increase of 192.11% from the latest price.
News
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on ADC Therapeutics (ADCT) to $5 from $10 and keeps a Buy rating on the shares. ADC Therapeutics faces increased regulatory…
ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year
Reports Q2 revenue $18.6M, consensus $18.9M. “We are pleased by our Q2 performance, which reflects continued commercial momentum and strong operational discipline through ongoing cost reduction effort...
ADC Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw stable ZYNLONTA revenues and reduced operating expenses, with a strong cash position supporting operations into 2028. Regulatory uncertainty surrounds LOTIS-5, but promising LOTIS-7 data and cost-saving measures position the company for future growth.
ADC Therapeutics Earnings release: Q2 2026
ADC Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ADC Therapeutics Slides: Q2 2026
ADC Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
ADC Therapeutics Earnings release: Q2 2026
ADC Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ADC Therapeutics Quarterly report: Q2 2026
ADC Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
ADC Therapeutics Slides: Corporate presentation
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company ev...
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial
ADC Therapeutics (ADCT) announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta in combination with the bispecific antib...
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therape...
ADC Therapeutics to reduce workforce by 17% globally
ADC Therapeutics (ADCT) announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA, or loncastuximab tesirine-lpyl, franchise. As part of t...
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical...
ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded ADC Therapeutics (ADCT) to Neutral from Buy without a price target The firm says the LOTIS-5 trial calls Zynlonta’s risk-benefit profile into question. The firm sees a…
ADC Therapeutics price target lowered to $5 from $8 at Stephens
Stephens analyst Sudan Loganathan lowered the firm’s price target on ADC Therapeutics (ADCT) to $5 from $8 and keeps an Overweight rating on the shares after LOTIS-5 top line data…
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among treated patients, despite meeting its main ...
ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded ADC Therapeutics (ADCT) to Sector Perform from Outperform with a price target of $2, down from $6, after the company announced results from their LOTIS-5 trial in…
ADC Therapeutics Transcript: Study result
The phase III LOTIS-5 trial in 2L+ DLBCL met its primary endpoint, showing improved PFS and higher CR rates for ZYNLONTA plus rituximab versus R-GemOx, with manageable but increased Grade 5 adverse events in elderly patients. Regulatory submission is planned for late 2026.
ADC Therapeutics Slides: Study result
ADC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
ADC Therapeutics Press release: Study result
ADC Therapeutics issued a press release on June 3, 2026, disclosing material business information to investors.
ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL
ADC Therapeutics (ADCT) announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating Zynlonta – loncastuximab tesirine-lpyl – in combination with rituximab in patients with relapsed o...
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confir...
ADC Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 net product revenues rose 15% year-over-year to $20M, with stable demand for ZYNLONTA and reduced operating expenses. Key clinical milestones, including LOTIS-5 top-line data, are expected in 2026, with revenue growth acceleration projected for 2027.